# Compass Pathways Q1 Earnings Call Highlights

- URL: https://theranews.net/blog/2026-05-17-compass-pathways-q1-earnings-call-highlights-9989a2/
- Published: 2026-05-17
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: thelincolnianonline
- Original report: https://www.thelincolnianonline.com/2026/05/16/compass-pathways-q1-earnings-call-highlights.html
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved. On the company’s first-quart

---
![Compass Pathways Q1 Earnings Call Highlights](/uploads/news-images/compass-pathways-q1-earnings-call-highlights-20260517080043.png)

---
*Originally reported by thelincolnianonline. [Read more](https://www.thelincolnianonline.com/2026/05/16/compass-pathways-q1-earnings-call-highlights.html)*

---

*Source: [https://www.thelincolnianonline.com/2026/05/16/compass-pathways-q1-earnings-call-highlights.html](https://www.thelincolnianonline.com/2026/05/16/compass-pathways-q1-earnings-call-highlights.html)*